Results 21 to 30 of about 692,682 (292)

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Diabetes, obesity and metabolism, 2022
To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin.
M. Kellerer, M. Kaltoft, J. Lawson, L. Nielsen, K. Strojek, Ömür Tabak, S. Jacob   +6 more
semanticscholar   +1 more source

Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes. [PDF]

Diabetes Obes Metab
Abstract Aims To explore outcome parameters related to achieving HbA1c goal (<7.0%) in subphenotypes of type 2 diabetes (T2D), either on basal insulin (BI) glargine 300 U/mL or 100 U/mL or switched to these BIs (≥42 U/day) alone or with pre‐prandial insulin.
Landgraf W, Owens DR, Frier BM, Bolli GB.   +3 more
europepmc   +2 more sources

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Diabetes, obesity and metabolism, 2022
To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) and lixisenatide (Lixi), in Asian Pacific people with suboptimally controlled type 2 diabetes (T2D) on metformin with or without a second oral antihyperglycaemic ...
Wenying Yang, Xiaolin Dong, Qingju Li, Zhifeng Cheng, Guoyue Yuan, Ming Liu, Jianzhong Xiao, Shenghong Gu, E. Niemoeller, Lijuan Chen, Lin Ping, E. Souhami   +11 more
semanticscholar   +1 more source

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. [PDF]

PLoS ONE, 2010
BACKGROUND: Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin.
Mark R Sommerfeld, Günter Müller, Georg Tschank, Gerhard Seipke, Paul Habermann, Roland Kurrle, Norbert Tennagels   +6 more
doaj   +1 more source

Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial

Diabetes, obesity and metabolism, 2022
To use continuous glucose monitoring (CGM)‐based time‐in‐range (TIR) as a primary efficacy endpoint to compare the second‐generation basal insulin (BI) analogues insulin glargine 300 U/ml (Gla‐300) and insulin degludec 100 U/ml (IDeg‐100) in adults with ...
T. Battelino, T. Danne, S. Edelman, P. Choudhary, E. Renard, J. Westerbacka, Bhaswati Mukherjee, V. Pilorget, Mathieu Coudert, R. Bergenstal   +9 more
semanticscholar   +1 more source

Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety

Медицинский совет, 2021
In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose ...
E. V. Biryukova, M. V. Shinkin, O. M. Mikheeva   +2 more
doaj   +1 more source

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks. DUAL VIII, a randomized trial designed to resemble clinical practice [PDF]

, 2020
This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N =
Aroda, V. R., Bardtrum, L., Dagdelen, S., Halladin, N., Haluzik, M., Orsy, P., Rodriguez, M., Sesti, G.   +7 more
core   +1 more source

Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for hypoglycaemia

Diabetes, obesity and metabolism, 2021
To compare time in range (TIR) with use of insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100) in people with type 2 diabetes.
R. Goldenberg, V. Aroda, L. Billings, A. Sia Louise Christiansen, Anders Meller Donatsky, Ehsan Parvaresh Rizi, G. Podgorski, K. Rašlová, D. Klonoff, R. Bergenstal   +9 more
semanticscholar   +1 more source

Evaluation of Early Administration of Insulin Glargine in the Acute Management of Diabetic Ketoacidosis.

Current Diabetes Reviews, 2021
BACKGROUND Few studies have evaluated the early use of insulin glargine in the management of diabetic ketoacidosis (DKA) patients. Early insulin glargine use in DKA was safe and associated with a trend towards faster DKA resolution.
Adham M. Mohamed, Jeannette Ploetz, M. Hamarshi   +2 more
semanticscholar   +1 more source

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial

Diabetes, obesity and metabolism, 2021
To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla‐300) versus insulin degludec 100 U/mL (IDeg‐100) in predefined (
G. Bolli, A. Cheng, B. Charbonnel, V. Aroda, J. Westerbacka, Z. Bosnyák, Emmanuelle Boëlle-Le-Corfec, J. Rosenstock   +7 more
semanticscholar   +1 more source